<DOC>
	<DOC>NCT01201161</DOC>
	<brief_summary>The purpose of this study was to assess the effect of ranibizumab in reducing intraoperative vitreous haemorrhage during pars plana vitrectomy, thus facilitating surgery and improving its anatomical and functional results in patients with advanced proliferative diabetic retinopathy and traction retinal detachment.</brief_summary>
	<brief_title>Ranibizumab for Diabetic Traction Retinal Detachment</brief_title>
	<detailed_description />
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Retinal Detachment</mesh_term>
	<mesh_term>Dissociative Disorders</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Temazepam</mesh_term>
	<criteria>Macular traction retinal detachment lasting three months or less secondary to diabetic retinopathy. Massive vitreous hemorrhage preventing from detailed posterior pole examination; Previous intraocular surgery other than cataract surgery Hemodialysis, known bleeding disorders or use of anticoagulants drugs other than aspirin Prothrombin time, partial thromboplastin time or platelet count without normal limits History of previous thromboembolic events</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Diabetic Retinopathy</keyword>
	<keyword>Retinal detachment</keyword>
	<keyword>Vitreous Hemorrhage</keyword>
	<keyword>Preoperative Ranibizumab</keyword>
	<keyword>pars plana vitrectomy</keyword>
</DOC>